Selected research
Industry Research
New Drug Modeling Solution Industry Research Report 2026
Market perspective
The global New Drug Modeling Solution market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the New Drug Modeling Solution market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the New Drug Modeling Solution market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the New Drug Modeling Solution market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of New Drug Modeling Solution include JSR Corporation(Crown Bioscience), Chemical Computing Group ULC, Nimbus Therapeutics, schrodinger, Inc, Genedata AG, Biognos AB, Compugen Ltd, Dassault Systemes and Acellera and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global New Drug Modeling Solution market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to New Drug Modeling Solution.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
New Drug Modeling Solution Market by Company
JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
lnstem(Leadscope)
New Drug Modeling Solution Segment by Type
Database
Software
Others
New Drug Modeling Solution Segment by Application
Drug Discovery and Development
Computational Physiological Medicine
Disease Modeling
Others
New Drug Modeling Solution Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global New Drug Modeling Solution market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of New Drug Modeling Solution and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of New Drug Modeling Solution.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of New Drug Modeling Solution companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Database
- Software
- Others
Applications
- Drug Discovery and Development
- Computational Physiological Medicine
- Disease Modeling
- Others
Companies covered
- JSR Corporation(Crown Bioscience)
- Chemical Computing Group ULC
- Nimbus Therapeutics
- schrodinger, Inc
- Genedata AG
- Biognos AB
- Compugen Ltd
- Dassault Systemes
- Acellera
- lnstem(Leadscope)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 New Drug Modeling Solution by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Database
- 2.2.3 Software
- 2.2.4 Others
- 2.3 New Drug Modeling Solution by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Drug Discovery and Development
- 2.3.3 Computational Physiological Medicine
- 2.3.4 Disease Modeling
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 New Drug Modeling Solution Breakdown Data by Type
- 3.1 Global New Drug Modeling Solution Historic Market Size by Type (2021-2026)
- 3.2 Global New Drug Modeling Solution Forecasted Market Size by Type (2027-2032)
4 New Drug Modeling Solution Breakdown Data by Application
- 4.1 Global New Drug Modeling Solution Historic Market Size by Application (2021-2026)
- 4.2 Global New Drug Modeling Solution Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global New Drug Modeling Solution Market Perspective (2021-2032)
- 5.2 Global New Drug Modeling Solution Growth Trends by Region
- 5.2.1 Global New Drug Modeling Solution Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 New Drug Modeling Solution Historic Market Size by Region (2021-2026)
- 5.2.3 New Drug Modeling Solution Forecasted Market Size by Region (2027-2032)
- 5.3 New Drug Modeling Solution Market Dynamics
- 5.3.1 New Drug Modeling Solution Industry Trends
- 5.3.2 New Drug Modeling Solution Market Drivers
- 5.3.3 New Drug Modeling Solution Market Challenges
- 5.3.4 New Drug Modeling Solution Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top New Drug Modeling Solution Players by Revenue
- 6.1.1 Global Top New Drug Modeling Solution Players by Revenue (2021-2026)
- 6.1.2 Global New Drug Modeling Solution Revenue Market Share by Players (2021-2026)
- 6.2 Global New Drug Modeling Solution Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of New Drug Modeling Solution Head Office and Area Served
- 6.4 Global New Drug Modeling Solution Players, Product Type & Application
- 6.5 Global New Drug Modeling Solution Manufacturers Established Date
- 6.6 Global New Drug Modeling Solution Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America New Drug Modeling Solution Market Size (2021-2032)
- 7.2 North America New Drug Modeling Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America New Drug Modeling Solution Market Size by Country (2021-2026)
- 7.4 North America New Drug Modeling Solution Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe New Drug Modeling Solution Market Size (2021-2032)
- 8.2 Europe New Drug Modeling Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe New Drug Modeling Solution Market Size by Country (2021-2026)
- 8.4 Europe New Drug Modeling Solution Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific New Drug Modeling Solution Market Size (2021-2032)
- 9.2 Asia-Pacific New Drug Modeling Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific New Drug Modeling Solution Market Size by Country (2021-2026)
- 9.4 Asia-Pacific New Drug Modeling Solution Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America New Drug Modeling Solution Market Size (2021-2032)
- 10.2 South America New Drug Modeling Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America New Drug Modeling Solution Market Size by Country (2021-2026)
- 10.4 South America New Drug Modeling Solution Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa New Drug Modeling Solution Market Size (2021-2032)
- 11.2 Middle East & Africa New Drug Modeling Solution Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa New Drug Modeling Solution Market Size by Country (2021-2026)
- 11.4 Middle East & Africa New Drug Modeling Solution Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 JSR Corporation(Crown Bioscience)
- 12.1.1 JSR Corporation(Crown Bioscience) Company Information
- 12.1.2 JSR Corporation(Crown Bioscience) Business Overview
- 12.1.3 JSR Corporation(Crown Bioscience) Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.1.4 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Product Portfolio
- 12.1.5 JSR Corporation(Crown Bioscience) Recent Developments
- 12.2 Chemical Computing Group ULC
- 12.2.1 Chemical Computing Group ULC Company Information
- 12.2.2 Chemical Computing Group ULC Business Overview
- 12.2.3 Chemical Computing Group ULC Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.2.4 Chemical Computing Group ULC New Drug Modeling Solution Product Portfolio
- 12.2.5 Chemical Computing Group ULC Recent Developments
- 12.3 Nimbus Therapeutics
- 12.3.1 Nimbus Therapeutics Company Information
- 12.3.2 Nimbus Therapeutics Business Overview
- 12.3.3 Nimbus Therapeutics Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.3.4 Nimbus Therapeutics New Drug Modeling Solution Product Portfolio
- 12.3.5 Nimbus Therapeutics Recent Developments
- 12.4 schrodinger, Inc
- 12.4.1 schrodinger, Inc Company Information
- 12.4.2 schrodinger, Inc Business Overview
- 12.4.3 schrodinger, Inc Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.4.4 schrodinger, Inc New Drug Modeling Solution Product Portfolio
- 12.4.5 schrodinger, Inc Recent Developments
- 12.5 Genedata AG
- 12.5.1 Genedata AG Company Information
- 12.5.2 Genedata AG Business Overview
- 12.5.3 Genedata AG Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.5.4 Genedata AG New Drug Modeling Solution Product Portfolio
- 12.5.5 Genedata AG Recent Developments
- 12.6 Biognos AB
- 12.6.1 Biognos AB Company Information
- 12.6.2 Biognos AB Business Overview
- 12.6.3 Biognos AB Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.6.4 Biognos AB New Drug Modeling Solution Product Portfolio
- 12.6.5 Biognos AB Recent Developments
- 12.7 Compugen Ltd
- 12.7.1 Compugen Ltd Company Information
- 12.7.2 Compugen Ltd Business Overview
- 12.7.3 Compugen Ltd Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.7.4 Compugen Ltd New Drug Modeling Solution Product Portfolio
- 12.7.5 Compugen Ltd Recent Developments
- 12.8 Dassault Systemes
- 12.8.1 Dassault Systemes Company Information
- 12.8.2 Dassault Systemes Business Overview
- 12.8.3 Dassault Systemes Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.8.4 Dassault Systemes New Drug Modeling Solution Product Portfolio
- 12.8.5 Dassault Systemes Recent Developments
- 12.9 Acellera
- 12.9.1 Acellera Company Information
- 12.9.2 Acellera Business Overview
- 12.9.3 Acellera Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.9.4 Acellera New Drug Modeling Solution Product Portfolio
- 12.9.5 Acellera Recent Developments
- 12.10 lnstem(Leadscope)
- 12.10.1 lnstem(Leadscope) Company Information
- 12.10.2 lnstem(Leadscope) Business Overview
- 12.10.3 lnstem(Leadscope) Revenue in New Drug Modeling Solution Business (2021-2026)
- 12.10.4 lnstem(Leadscope) New Drug Modeling Solution Product Portfolio
- 12.10.5 lnstem(Leadscope) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst